Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Colorectal Cancer: Dosing Strategies With Regorafenib

February 10th 2017

Trifluridine/Tipiracil in Advanced Colorectal Cancer

February 10th 2017

Setting Expectations in Third-Line Colorectal Cancer

February 10th 2017

Long-Term Therapeutic Strategies in Colorectal Cancer

February 10th 2017

Selective Internal Radiation Therapy in Colorectal Cancer

February 10th 2017

Intrahepatic Radiation in Colorectal Cancer

February 10th 2017

Management of Liver-Dominant Unresectable Colorectal Cancer

February 10th 2017

Neoadjuvant/Adjuvant Approaches in Colorectal Cancer

February 10th 2017

Curative Intent in Oligometastatic Colorectal Cancer

February 10th 2017

MSI Status and Immunotherapy in Advanced Colorectal Cancer

February 10th 2017

Antibody Selection and Right- Versus Left-Sided Colorectal Cancer

February 10th 2017

Understanding Tumor Sidedness in Colorectal Cancer

February 10th 2017

ADI-PEG 20 Added to Standard Therapy Shows Potential Promise in Pancreatic Cancer

February 10th 2017

The addition of ADI-PEG 20, a pegylated form of an arginine-depleting enzyme, to nab-paclitaxel and gemcitabine showed encouraging activity and minimal additional toxicity in the treatment of patients with advanced pancreatic adenocarcinoma.

Dr. Loaiza-Bonilla on Trial of Left- and Right-Sided Colorectal Cancer

February 9th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specializing in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses a clinical trial focused on the differences between left- and right-sided tumors of colorectal cancer (CRC).

Expert Discusses PD-1 Success in MSI-H Colorectal Cancer

February 9th 2017

Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.

Dr. Ku on Immunotherapy in Gastric and Esophageal Cancer

February 9th 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Analysis Confirms Survival Benefit With Nanoliposomal Irinotecan Regimen in Pancreatic Cancer

February 7th 2017

Patients with metastatic pancreatic ductal adenocarcinoma lived longer and had slowing of disease progression when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.

Atezolizumab/Bevacizumab Combo Attains 90% DCR in MSI-High mCRC

February 7th 2017

Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.

Little Correlation Between Phase II, III Trials in Advanced Pancreatic Cancer

February 7th 2017

Few phase II trials in advanced pancreatic cancer conformed to recommended design characteristics for pilot trials, a contributing factor to lack of success in the disease, Australian investigators reported.

Napabucasin Linked With Objective Responses in Advanced CRC

February 7th 2017

As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab, according to evaluable results of a study presented at the 2017 Gastrointestinal Cancers Symposium.